Lercanidipin Amarox

Lercanidipine, the active ingredient in Lercanidipin Amarox, is a calcium channel blocker presented as an oral tablet for oral use. It is used to treat essential hypertension in adult patients. GNH USA supplies Lercanidipin Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker indicated for the management of hypertension. - Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: provides vascular relaxation to reduce elevated systolic pressure. - Secondary hypertension (when appropriate): assists in achieving blood pressure control alongside other antihypertensive agents.

Lercanidipine may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially on standing.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat requiring emergency care. - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations or hepatitis.

Before initiating therapy, consider the following safety measures. - Pregnancy: safety not established; avoid unless clearly needed. - Renal impairment: monitor blood pressure and adjust therapy if required. - Hepatic impairment: use with caution and observe for increased exposure. - Concomitant CYP3A4 inhibitors: may raise plasma levels, increasing risk of adverse effects. - Abrupt discontinuation: may cause rebound hypertension; taper when stopping. - Store at room temperature: keep in the original pack, protect from moisture and light.

Lercanidipine can interact with several drug classes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lercanidipine concentrations. - Grapefruit juice: can raise plasma levels and enhance hypotensive effect. - Other potent antihypertensives (e.g., ACE inhibitors, ARBs): may cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Diuretics: additive hypotensive action, monitor electrolytes. - Beta‑blockers: combined use may lead to greater blood pressure lowering.